To address the role of tumor cell necroptosis in cancer immunotherapy with ICI, we used CRISPR-mediated somatic mutagenesis to generate polyclonal tumor cell lines that lack critical components of the necroptotic cell death molecular machinery (RIPK3−/−, MLKL−/−). Here, RIPK3 is linked to cancer.